Analyst Ratings for [AZN] Astrazeneca PLC

4/15/25	Initiated	Outperform	X
AZN AstraZeneca Exane BNP Paribas
$75
2/13/25	Upgrades	Neutral Buy	X
AZN AstraZeneca UBS
2/12/25	Initiated	Overweight	X
AZN AstraZeneca Morgan Stanley
11/20/24	Upgrades	Sell Neutral	X
AZN AstraZeneca UBS
11/6/24	Upgrades	Sell Hold	X
AZN AstraZeneca Deutsche Bank
9/13/24	Downgrades	Hold Sell	X
AZN AstraZeneca Deutsche Bank
5/30/24	Initiated	Buy	X
AZN AstraZeneca Goldman
$97
4/16/24	Upgrades	Sell Hold	X
AZN AstraZeneca Deutsche Bank
2/8/24	Downgrades	Hold Sell	X
AZN AstraZeneca Deutsche Bank
1/23/24	Initiated	Overweight	X
AZN AstraZeneca Morgan Stanley
$85
1/16/24	Resumed	Sell	X
AZN AstraZeneca UBS
1/3/24	Downgrades	Buy Hold	X
AZN AstraZeneca Jefferies
$78.50 $70
12/18/23	Initiated	Buy	X
AZN AstraZeneca HSBC Securities
$78
7/14/23	Initiated	Buy	X
AZN AstraZeneca HSBC Securities
7/12/23	Upgrades	Neutral Buy	X
AZN AstraZeneca UBS
7/5/23	Downgrades	Buy Hold	X
AZN AstraZeneca Deutsche Bank
4/11/23	Upgrades	Eq-Weight Overweight	X
AZN AstraZeneca Morgan Stanley
1/5/23	Initiated	Outperform	X
AZN AstraZeneca BMO Capital Markets
$82
9/15/22	Downgrades	Outperform Neutral	X
AZN AstraZeneca Credit Suisse
9/7/22	Downgrades	Overweight Eq-Weight	X
AZN AstraZeneca Morgan Stanley
8/29/22	Upgrades	Hold Buy	X
AZN AstraZeneca Argus
$75
6/14/22	Downgrades	Buy Neutral	X
AZN AstraZeneca UBS
2/11/22	Upgrades	Sell Hold	X
AZN AstraZeneca DZ Bank
12/7/21	Downgrades	Buy Hold	X
AZN AstraZeneca Jefferies
4/12/21	Downgrades	Buy Hold	X
AZN AstraZeneca Argus
3/16/21	Upgrades	Hold Buy	X
AZN AstraZeneca Jefferies
2/25/21	Upgrades	Neutral Buy	X
AZN AstraZeneca UBS
1/15/21	Initiated	Buy	X
AZN AstraZeneca Deutsche Bank
4/2/19	Downgrades	Neutral Sell	X
AZN AstraZeneca UBS
2/5/19	Initiated	Outperform	X
AZN AstraZeneca Exane BNP Paribas
1/25/19	Upgrades	Hold Buy	X
AZN AstraZeneca Shore Capital
12/11/18	Resumed	Hold	X
AZN AstraZeneca Jefferies
10/9/18	Initiated	Buy	X
AZN AstraZeneca Guggenheim
8/16/18	Downgrades	Buy Hold	X
AZN AstraZeneca Jefferies
3/19/18	Upgrades	Hold Buy	X
AZN AstraZeneca Jefferies
2/6/18	Reiterated	Mkt Perform	X
AZN AstraZeneca Leerink Partners
$36 $38
2/5/18	Reiterated	Outperform	X
AZN AstraZeneca Bernstein
$40 $42

AZN Astrazeneca PLC

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.